13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q3 2024. See the latest, Q2 2026 →

Reported value

$1.84B

−6.7% on the quarter before

Positions

2 new · 2 sold out

Top 10

90.2%

of the value

Est. gain

−$75.2M

on stocks held all quarter

Est. return

−4.0%

on those stocks since Q2 2024

Filed

Nov 8, 2024

On SEC EDGAR ↗

Positions as of Sep 30, 2024, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2024. Striped tiles are options.

Gitlab Inc27%

Arm Holdings Plc15%

Revolution Medicines Inc10%

Freshworks Inc10%

CrowdStrike6.5%UiPath4.9%Tempus AI4.8%

Planet Labs Pbc3.9%

Dexcom Inc3.8%

Verve Therapeutics Inc3.2%

Prime Medicine Inc3.2%

18 others1.0%

0.7%

0.6%

Gitlab Inc27%

Arm Holdings Plc15%

Revolution Medicines Inc10%

Freshworks Inc10%

CrowdStrike6.5%UiPath4.9%Tempus AI4.8%

Planet Labs Pbc3.9%

Dexcom Inc3.8%

Verve Therapeutics Inc3.2%

Prime Medicine Inc3.2%

18 others1.0%

0.7%

0.6%

Largest buys

Since Q2 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Freshworks Inc~$44.4MAdded · 7.9% → 10.1%+3,870,000 shares
Benson Hill Inc~$3.2MNew · 0.0% → 0.2%+438,635 shares
Genedx Holdings Corp~$963,855New · 0.0% → 0.1%+22,711 shares

Largest sells

Since Q2 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Snowflake~$48.4MCut · 3.7% → 0.7%−421,050 shares
Revolution Medicines Inc~$47.7MCut · 10.4% → 10.5%−1,050,900 shares
Illumina Inc~$5.6MSold out · 0.3% → 0.0%−53,470 shares
Benson Hill Inc~$2.3MSold out · 0.1% → 0.0%−15,352,271 shares

Holdings

As of Sep 30, 2024. Changes are in shares against Jun 30, 2024, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Gitlab IncCLASS A COM · shares 0% · price +3.7%	27.3%	24.6%	$502.9M	9.8M	0%	$51.54	$49.72	+3.7%	+$17.8M
2	Arm Holdings PlcSPONSORED ADS · shares 0% · price −12.6%	15.2%	16.3%	$280.4M	2.0M	0%	$143.01	$163.62	−12.6%	−$40.4M
3	Revolution Medicines IncCOM · shares −20% · price +16.9%	10.5%	10.4%	$193.0M	4.3M	−20%	$45.35	$38.81	+16.9%	+$27.8M
4	Freshworks IncCLASS A COM · shares +31% · price −9.5%	10.1%	7.9%	$186.1M	16.2M	+31%	$11.48	$12.69	−9.5%	−$14.9M
5	CrowdStrikeCL A · shares 0% · price −26.8%	6.5%	8.3%	$120.0M	427,895	0%	$280.47	$383.19	−26.8%	−$44.0M
6	UiPathCL A · shares 0% · price +0.9%	4.9%	4.5%	$90.0M	7.0M	0%	$12.80	$12.68	+0.9%	+$844,121
7	Tempus AICL A · shares 0% · price +61.7%	4.8%	2.7%	$87.8M	1.6M	0%	$56.60	$35.00	+61.7%	+$33.5M
8	Planet Labs PbcCOM CL A · shares 0% · price +19.9%	3.9%	3.0%	$71.2M	31.9M	0%	$2.23	$1.86	+19.9%	+$11.8M
9	Dexcom IncCOM · shares 0% · price −40.9%	3.8%	6.0%	$69.5M	1.0M	0%	$67.04	$113.38	−40.9%	−$48.1M
10	Verve Therapeutics IncCOM · shares 0% · price −0.8%	3.2%	3.1%	$59.8M	12.3M	0%	$4.84	$4.88	−0.8%	−$493,963
11	Prime Medicine IncCOM · shares 0% · price −24.7%	3.2%	3.9%	$58.3M	15.1M	0%	$3.87	$5.14	−24.7%	−$19.1M
12	SnowflakeCL A · shares −79% · price −15.0%	0.71%	3.7%	$13.2M	114,554	−79%	$114.86	$135.09	−15.0%	−$2.3M
13	Sana Biotechnology IncCOM · shares 0% · price −23.8%	0.64%	0.78%	$11.7M	2.8M	0%	$4.16	$5.46	−23.8%	−$3.7M
14	Relay Therapeutics IncCOM · shares 0% · price +8.6%	0.60%	0.52%	$11.1M	1.6M	0%	$7.08	$6.52	+8.6%	+$878,501
15	Vera Therapeutics IncCL A · shares 0% · price +22.2%	0.58%	0.44%	$10.7M	241,264	0%	$44.20	$36.18	+22.2%	+$1.9M
16	Oscar Health IncCL A · shares 0% · price +34.1%	0.55%	0.39%	$10.2M	481,988	0%	$21.21	$15.82	+34.1%	+$2.6M
17	Lyell Immunopharma IncCOM · shares 0% · price −4.8%	0.44%	0.43%	$8.1M	5.9M	0%	$1.38	$1.45	−4.8%	−$410,558
18	Beam Therapeutics IncCOM · shares 0% · price +4.6%	0.43%	0.38%	$7.9M	321,604	0%	$24.50	$23.43	+4.6%	+$344,116
19	Monte Rosa Therapeutics IncCOM · shares 0% · price +41.7%	0.42%	0.28%	$7.8M	1.5M	0%	$5.30	$3.74	+41.7%	+$2.3M
20	Dianthus Therapeutics IncCOM · shares 0% · price +5.8%	0.31%	0.27%	$5.7M	208,697	0%	$27.38	$25.88	+5.8%	+$313,046
21	Tscan Therapeutics IncCOM · shares 0% · price −14.9%	0.29%	0.32%	$5.4M	1.1M	0%	$4.98	$5.85	−14.9%	−$937,060
22	Desktop Metal IncCOM CL A · shares 0% · price +13.1%	0.28%	0.23%	$5.2M	1.1M	0%	$4.67	$4.13	+13.1%	+$596,631
23	Foghorn Therapeutics IncCOM · shares 0% · price +61.9%	0.25%	0.15%	$4.7M	500,901	0%	$9.31	$5.75	+61.9%	+$1.8M
24	Benson Hill IncCOM NEW · shares New	0.17%	—	$3.2M	438,635	New	$7.20	—	—	—
25	Autolus Therapeutics PlcSPON ADR · shares 0% · price +4.3%	0.14%	0.12%	$2.5M	698,262	0%	$3.63	$3.48	+4.3%	+$104,739
	Total · 42 positions	100%		$1.84B						−$75.2M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2024 to Q3 2024: 38 stocks held throughout, down $75.2M (−4.0%).

Tempus AI+$33.5M+62%
Revolution Medicines Inc+$27.8M+17%
Gitlab Inc+$17.8M+4%
Planet Labs Pbc+$11.8M+20%
Oscar Health Inc+$2.6M+34%
Freshworks Inc−$14.9M−10%
Prime Medicine Inc−$19.1M−25%
Arm Holdings Plc−$40.4M−13%
CrowdStrike−$44.0M−27%
Dexcom Inc−$48.1M−41%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗